The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.

Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.

JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.

The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.

In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.

Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.

Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.

Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.